期刊
AUTOIMMUNITY REVIEWS
卷 7, 期 5, 页码 391-397出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.autrev.2008.03.004
关键词
catalytic antibodies; proteolytic IgM; amyloid beta peptide; Alzheimer's disease; immunotherapy
类别
资金
- NIA NIH HHS [R01 AG025304-01A1, R01 AG025304, U01 AG017173-03S1, U01 AG017173-03, R01 AG025304-03, U01 AG017173-03S2, U01 AG017173-02, U01 AG017173-01A1, R01 AG025304-02, 1R01 AG 025304] Funding Source: Medline
Immunoglobulins (Igs) that bind amyloid beta peptide (A beta) are under clinical trials for immunotherapy of Alzheimer disease (AD). We have identified IgMs and recombinant Ig fragments that hydrolyze A beta. Hydrolysis of peripheral A beta by the IgMs may induce increased A beta release from the brain. The catalytic IgMs are increased in AD patients, presumably reflecting a protective autoimmune response. Reduced A beta aggregation and neurotoxicity attributable to the catalytic function were evident. These findings provide a foundation for development of catalytic Igs for AD immunotherapy. (C) 2008 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据